Boston Scientific (BSX) Equity Average (2009 - 2026)

Boston Scientific has disclosed Equity Average across 18 years of filings, most recently posting $25.2 billion for Q1 2026.

• Equity Average for Q1 2026 came in at $25.2 billion, up 13.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.2 billion (up 13.84% YoY), and the FY2025 annual result was $23.0 billion, up 11.39% from the prior year.
• Equity Average came in at $25.2 billion for Q1 2026 at Boston Scientific, up from $23.9 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $25.2 billion in Q1 2026 to a low of $62.5 million in Q2 2024.
• The 5-year median for Equity Average is $10.9 billion (2025), against an average of $13.9 billion.
• Peak annual rise in Equity Average reached 17408.8% in 2025, while the deepest fall reached 9.26% in 2025.
• Boston Scientific's Equity Average stood at $8.4 billion in 2022, then soared by 128.89% to $19.3 billion in 2023, then advanced by 10.52% to $21.4 billion in 2024, then grew by 12.02% to $23.9 billion in 2025, then rose by 5.17% to $25.2 billion in 2026.
• The last three Equity Average figures came in at $25.2 billion (Q1 2026), $23.9 billion (Q4 2025), and $11.5 billion (Q3 2025), per Business Quant data.